Single-Dose Parvo Treatment gets USDA Approval: Elanco’s therapy for canine parvovirus gets first nod
Elanco’s Canine Parvovirus Monoclonal Antibody treatment may provide a less intensive solution by targeting the virus with single-dose efficacy in dogs.
Dogs infected with canine parvovirus (CPV) will soon have access to a single, intravenous dose treatment for the potentially deadly virus.
Elanco Animal Health, Inc., has received a conditional license from the U.S. Department of Agriculture (USDA) for its injectable Canine Parvovirus Monoclonal Antibody solution. The treatment, which represents a therapeutic alternative to traditional, intensive supportive therapy options, can be administered to CPV-infected dogs eight weeks of age or older, regardless of vaccination status.
Dogs infected with canine parvovirus (CPV) can soon receive a single, intravenous dose treatment option for the potentially deadly virus.
“[This] announcement is a game changer for pet owners and veterinarians,” says Kristin Zersen, DVM, DACVECC, assistant professor of small animal emergency and critical care at Colorado State University Veterinary Teaching Hospital. “Parvovirus is an unpredictable disease that causes significant strain on pet owners and is labor intensive and stressful for shelters and veterinary clinic staff.”
CPV is among the most contagious and deadly viruses a dog can contract, with a 91 percent mortality rate if not treated with supportive care, Elanco reports. The newly approved treatment may provide a less intensive and more effective solution than supportive care alone by targeting the virus with single-dose efficacy and a strong safety profile in healthy dogs.
“It’s lifechanging and industry-defining to be able to offer a proven solution to canine parvovirus that limits the need for hospitalization, reducing the impact this disease has on hundreds of thousands of dogs each year,” Dr. Zersen says.
“Elanco is proud to bring to market this first-in-class treatment that will help save puppies’ lives, while alleviating the emotional and financial burden of both pet owners and veterinary care teams,” adds Elanco’s president and CEO, Jeff Simmons.
The Canine Parvovirus Monoclonal Antibody is expected to begin shipping in the coming weeks, pending individual state approvals.
Fight parvo with Canine Parvovirus Monoclonal Antibody
With just one intravenous dose, Canine Parvovirus Monoclonal Antibody (CPMA) may shorten the course of the disease and improve outcomes.
Two components. One powerful product.
CPMA is composed of a dog constant region and a rat variable region. These two elements work together to neutralize canine parvovirus in vivo by selectively binding and blocking the virus from entering and destroying enterocytes.
After challenged with virulent CPV-2b, zero dogs died when treated with Canine Parvovirus Monoclonal Antibody.1
ABOUT ELANCO
Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we’re driven by our vision of Food and Companionship Enriching Life and our approach to sustainability, Elanco Healthy Purpose™– all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
Source-https://www.veterinarypracticenews.com/single-dose-parvo-treatment-gets-usda-approval
